UCB's Global Corporate Website
Welcome to UCB in the United States

Oct

18

BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

Feb

10

Partnering With the Dermatology Community to Improve Health Equity

Aug

11

Setting New Standards in Diversity for Dermatology Clinical Trials

One place where we can learn more about psoriasis in people of color is in clinical trials. However, people with skin of color are drastically underrepresented in clinical trials for dermatology. The lack of diversity in clinical trials means that medications developed for conditions like psoriasis may not work as effectively for people with skin of color, and ultimately, the health equity gap continues to widen.

 

Jun

07

Disease Spotlight: Hidradenitis Suppurativa

At UCB, people are at the heart of everything we do and part of our commitment to delivering impactful solutions for people whose lives have been challenged by severe disease is by deeply understanding their disease. This week is Hidradenitis Suppurativa (HS) Awareness Week and we’re sharing information on this lesser-known inflammatory, chronic autoimmune skin disease.

Mar

26

New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting

Mar

25

UCB at the 2022 AAD Annual Meeting: Our Commitment to Advancing Science in Dermatology

 

 

Dec

16

Positive Top-Line Results for Bimekizumab in Phase 3 Ankylosing Spondylitis Trial

Oct

22

UCB Presents Number Needed to Treat Analysis for Bimekizumab in Moderate to Severe Plaque Psoriasis at AMCP Nexus

UCB today announced new data from a network meta-analysis (NMA) demonstrating that bimekizumab was associated with the lowest number needed to treat (NNT) to achieve Psoriasis Area and Severity Index (PASI) 90 and PASI 100 skin clearance levels compared with 12 other approved biologic therapies used for moderate to severe plaque psoriasis within 16 weeks. These results were presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2021, October 18-21. 

Oct

16

Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab

Sep

29

New Bimekizumab Two-Year Data in Moderate to Severe Plaque Psoriasis Presented at the 30th European Academy of Dermatology and Venereology Congress